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Respiratory syncytial virus (RSV) is a common infection that affects most
infants by the age of two, as well as a large percentage of the elderly
population. For infants under one year, RSV is the most common cause of
bronchiolitis and pneumonia, and each year RSV leads to about 58,000
hospitalizations and 2.1 million outpatient visits for children under five in the
United States alone1. On a global scale, 6.7 percent of deaths are due to
complications from RSV, which is the highest fatality rate among all
pathogens except malaria2. Additionally, about 177,000 adults over 65 are
hospitalized and 14,000 within this age group die annually in the U.S. due to
the virus1. Currently, the majority of prevention lies in the hands of the
caretakers: wash hands frequently and before touching babies, avoid contact
with babies if sick or have babies wear masks, keep young children away
from babies, and avoid crowds during outbreaks3. A monoclonal antibody
has been approved by the Food and Drug Administration, and has shown
reduced hospitalization rates of 45 to 55 percent. However, this method
requires monthly injection during RSV season, requiring about five doses4. In
order to improve the lives of so many, this project aims to develop a vaccine
for RSV by focusing on the fusion (F) glycoprotein in the trimer form. This
protein is necessary for the virus to infect, as it assists the virus in fusing to
the plasma membrane of the target cell, and therefore assists in the insertion
of viral RNA into target cells and in spreading the virus to other cells5.
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Figure 2. Proteins separated by SDS-PAGE.
Reference bands on the left display the
location of specified molecular weights. F is
expressed, as it is slightly less than 69kDa.
Lane 1 was the ladder, Lane 2 was a
negative, Lane 3 was cell extract after Ni-
resin, and Lane 4 was from after resin
release.
Figure 1. Crystal structure
of the F protein, monomer
form. Segment A, acting as
a membrane anchor, was
removed to make F
soluble, and a trimerization
domain was added in its
place. Segment B binds to
the cellular receptor and
should be targeted by the
immune system.
Figure 4. Antibody titers present in mice
following injection. Adjuvants metformin
(Met.) and methyl pyruvate (Methyl) act on
the mitochondria, and were administered
with F monomer. F alone (Sham) was also
tested as a control for typical F vaccines.
The end titer represents total viral-specific
antibodies; neutralization titer represents
antibodies functional against RSV entry.
Figure 3. DNA gel
electrophoresis performed
on the F gene, the pOET
vector, and F inserted into
the vector. The two bands
in the pOET + F show the F
gene was present in the
baculovirus shuttle vector.
The shuttle vector was then
used in insect cell (Sf21)
transfections to make
recombinant virus. The
virus was amplified in more
insect cells and titered for
infection.
1. Manufacture recombinant F in the trimer form
 Clone F – grow up bacteria from colonies
 Miniprep – isolate the plasmids (F and baculovirus shuttle vector)
 Cut – cut plasmids with restriction enzymes
 Zap – break down bacteria cell membrane to integrate gene
 Gel electrophoresis – separate DNA fragments by size
 Purification – extract desired DNA from gel
 Plate – grow colonies with F insert
 PCR – confirm F gene insertion into vector
2. Express high quantities of F
 Clone F – grow up bacteria from colonies
 Midiprep – isolate the plasmids
 Transfections – expose F to various cell lines
• Baby hamster kidney (BHK) and insect cell lines
 SDS-PAGE – separate protein fragments by size
 Western Blot – transfer gel to membrane to identify proteins present
 Histidine purification by Ni-resin for recombinant F protein
3. Test immunogenicity of F in mice with adjuvants
 Vaccinations – inject F (2x 2-wks apart) and adjuvants (daily)
 Bleed mice – take blood samples from mice two weeks
post-vaccination
 ELISA – quantify antibodies against F from blood samples
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Many studies have concentrated on F protein vaccine but have failed in
clinical trials
 We hypothesized that an F protein that “looks” more native to the
viral structure would be more efficacious but would likely not protect
fully
 We tested whether we could enhance and broaden the immune
response to F monomer protein through use of mitochondrial
adjuvants
 We sought to make a recombinant F protein that folds into the native
trimeric form
Specially, we found:
 F has been expressed in various cell lines but expresses highest in
our baculovirus system
 Antibodies formed in mice against the F protein of RSVa and RSVb
strains of virus
• Use of adjuvants that act on the mitochondria appear to enhance
the levels of total and functional antibodies to RSV
By focusing on the trimer form, we believe that we can further enhance the
immune response to the F protein and better block viral entry
 Further testing on mice using additional mitochondrial adjuvants will be
done to determine an optimal choice
 Perform confirmation studies using native protein gels and
chromatography to confirm our recombinant protein is trimeric
 Vaccination with trimeric F will be substituted for monomeric F to
determine whether we can get enhanced neutralizing antibodies
 Challenge studies are planned to determine whether mice are protected
from the virus and whether any protection correlates with neutralizing
antibody titers
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